The global GLP-1 receptor agonist market was valued at USD 53.46 billion in 2024 and is projected to reach USD 156.71 billion by 2030, expanding at a CAGR of 17.46% from 2025 to 2030. This impressive growth is driven by the launch of new glucagon-like peptide-1 (GLP-1) receptor agonist products, a strong pipeline targeting diabetes and obesity applications, and the high therapeutic efficacy of these drugs.
### Market Drivers
In May 2024, Innovent Biologics announced that its type 2 diabetes drug candidate, mazdutide, outperformed Eli Lilly’s Trulicity (dulaglutide) in a Phase III trial. The study confirmed that mazdutide was superior in glycemic control and delivered multiple cardiometabolic benefits, including weight reduction and improvements in blood lipid levels, liver enzymes, serum uric acid, and blood pressure.
The rising prevalence of obesity and diabetes is a major factor fueling market expansion. Individuals who are overweight or obese face a significantly higher risk of developing type 2 diabetes and cardiovascular diseases. Currently, the growing global obesity rate is considered one of the most serious public health challenges. According to the World Heart Federation, nearly 2.3 billion children and adults worldwide suffer from obesity or overweight conditions. Similarly, the Obesity Action Coalition (OAC) reports that over 90% of individuals with type 2 diabetes are either overweight or obese. This expanding patient base is expected to accelerate demand for GLP-1 receptor agonist therapies globally.
### Advantages of GLP-1 Receptor Agonists
GLP-1 drugs offer distinct advantages over traditional medicines, which, along with rising R&D investments, further propel the market. These therapies have been associated with weight loss or weight neutrality, a critical benefit for diabetic patients since obesity exacerbates the condition. Their appetite-suppressing effects and delayed gastric emptying contribute significantly to effective weight management.
In November 2023, Novo Nordisk announced plans to invest approximately 16 billion Danish kroner (around USD 2.32 billion / €2.14 billion) to develop advanced GLP-1 drugs, highlighting strong industry commitment to innovation and market expansion.
### Key Market Trends & Insights
– **Regional Performance:** North America accounted for 77.72% of the global revenue in 2024, with the U.S. holding the largest market share within the region.
– **Product Segment:** The Ozempic segment dominated the market with a 34.17% share in 2024.
– **Distribution Channels:** Hospital pharmacies led with a 55.09% revenue share in 2024.
– **Applications:** The type 2 diabetes mellitus segment dominated in 2024 and is projected to grow at a CAGR of 17.06% during the forecast period.
– **Route of Administration:** The parenteral segment held the largest share in 2024 and is expected to grow at a CAGR of 17.42% from 2025 to 2030.
### Market Size & Forecast
| Year | Market Size (USD Billion) |
|——-|—————————–|
| 2024 | 53.46 |
| 2030 (Projected) | 156.71 |
– **CAGR (2024-2030):** 17.46%
– **Largest Market (2024):** North America
– **Fastest Growing Region:** Asia Pacific
[Download a free sample PDF of the GLP-1 Receptor Agonist Market Intelligence Study by Grand View Research.]
### Competitive Landscape
Key players operating in the GLP-1 receptor agonist market include AstraZeneca, Sanofi, Novo Nordisk A/S, and Eli Lilly and Company. These companies leverage their extensive customer bases and strong brand equity to maintain high-quality standards and expand market reach. Significant investments in infrastructure enable efficient processing and analysis of large sample volumes. Strategic collaborations with distributors and partner firms further strengthen their market presence.
Emerging players such as Hanmi Pharm. Co., Ltd, Eccogen, and D&D Pharmatech are focusing on securing government funding and institutional support while introducing innovative products to explore untapped growth opportunities.
**Prominent Companies Include:**
– Eli Lilly and Company
– Sanofi
– Novo Nordisk A/S
– AstraZeneca
Explore Horizon Databook, the world’s most comprehensive market intelligence platform by Grand View Research.
### Conclusion
The global GLP-1 receptor agonist market is poised for strong growth, supported by increasing obesity and diabetes prevalence, expanding product pipelines, and rising R&D investments. Technological innovations and strategic collaborations among key industry players are expected to further accelerate the adoption of GLP-1 receptor agonists worldwide.
https://express-press-release.net/news/2025/11/13/1719992